- Home
- FRD vs ELTX Comparison
FRD vs ELTX Comparison
Compare FRD & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- ELTX
- Stock Information
- Founded
- FRD 1965
- ELTX 2011
- Country
- FRD United States
- ELTX United States
- Employees
- FRD N/A
- ELTX N/A
- Industry
- FRD Steel/Iron Ore
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- ELTX Health Care
- Exchange
- FRD Nasdaq
- ELTX Nasdaq
- Market Cap
- FRD 114.4M
- ELTX 121.7M
- IPO Year
- FRD N/A
- ELTX N/A
- Fundamental
- Price
- FRD $16.50
- ELTX $7.85
- Analyst Decision
- FRD
- ELTX Strong Buy
- Analyst Count
- FRD 0
- ELTX 2
- Target Price
- FRD N/A
- ELTX $9.50
- AVG Volume (30 Days)
- FRD 59.9K
- ELTX 54.0K
- Earning Date
- FRD 06-12-2025
- ELTX 08-12-2025
- Dividend Yield
- FRD 0.97%
- ELTX N/A
- EPS Growth
- FRD N/A
- ELTX N/A
- EPS
- FRD 0.87
- ELTX N/A
- Revenue
- FRD $444,600,000.00
- ELTX N/A
- Revenue This Year
- FRD N/A
- ELTX N/A
- Revenue Next Year
- FRD N/A
- ELTX N/A
- P/E Ratio
- FRD $18.93
- ELTX N/A
- Revenue Growth
- FRD N/A
- ELTX N/A
- 52 Week Low
- FRD $12.24
- ELTX $3.34
- 52 Week High
- FRD $19.12
- ELTX $9.99
- Technical
- Relative Strength Index (RSI)
- FRD 50.72
- ELTX 58.06
- Support Level
- FRD $15.65
- ELTX $7.70
- Resistance Level
- FRD $16.75
- ELTX $8.05
- Average True Range (ATR)
- FRD 0.60
- ELTX 0.33
- MACD
- FRD -0.02
- ELTX -0.10
- Stochastic Oscillator
- FRD 52.16
- ELTX 42.03
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.